CorMedix Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $129M | ↑+312.1% | $14M | — | 46.0% |
| 2025-09-30 | $104M | ↑+810.2% | $109M | ↑+4009.6% | 49.2% |
| 2025-06-30 | $40M | ↑+4829.4% | $20M | ↑+240.1% | 49.2% |
| 2025-03-31 | $39M | — | $21M | ↑+242.7% | 51.5% |
| 2024-12-31 | $31M | — | — | — | — |
| 2024-09-30 | $11M | — | $-3M | ↑+71.5% | -28.7% |
| 2024-06-30 | $806K | — | $-14M | ↓-25.5% | -1898.1% |
| 2024-03-31 | — | — | $-14M | ↓-36.9% | — |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 63 quarters
margin trajectory tells the operating-leverage storyGo deeper
CRMD Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyCRMD Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics